ArticleJournal of translational medicine2025
Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-TGFβ axis and immune suppression in aggressive thyroid cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Identification and assessment ofOncology letters · 2026Article
- Microenvironmental Control of Thyroid Cancer Plasticity and Radioiodine Resistance.International journal of molecular sciences · 2026Review
- FN1Oncogene · 2026Article
- Cancer-associated fibroblasts in thyroid cancer stroma correlate with tumour progression and desmoplasia: a histopathological study.Thyroid research · 2026Article
- Theranostic and Radionuclide-based Treatment Approaches for Radioiodine-refractory Thyroid Cancer: From Biology to Clinical Application.Molecular imaging and biology · 2026Review
- The tumor immune microenvironment of thyroid cancer and colorectal cancer: cellular crosstalk and therapeutic implications.Frontiers in immunology · 2026Review
- PRELP-associated transcriptomic remodeling links alternative splicing and immune checkpoint blockade outcome in melanoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment options of aggressive thyroid carcinoma (TC) is limited due to its aggressiveness. Therefore, increased knowledge of the role of tumor intrinsic immune escape mechanisms and the microenvironment contributing to metastases formation is essential to improve the patients' outcome. These include extracellular matrix (ECM) components, cancer-associated fibroblasts (CAFs) and the expression of the fibroblast activation protein (FAP) known to be involved in immune evasion, disease progression and a worse prognosis of thyroid carcinoma (TC) patients.
methodsThe Cancer Genome Atlas (TCGA) and Human Protein Atlas datasets of TC specimens as well as tissue microarrays (TMA) consisting of 187 TC samples were analyzed for marker expression and immune cell infiltration. TC cell lines treated with recombinant FAP, a FAP inhibitor, transfected with siRNA-FAP plasmids and/or co-cultured with CAFs were subjected to qPCR, Western blot analyses and flow cytometry, cell supernatants to ELISA for cytokine secretion, the TMAs to conventional immunohistochemistry (IHC).
resultsImmunohistochemical staining and bioinformatics analyses of publicly available mRNA and protein expression profiles revealed a significant positive correlation between high FAP and fibronectin 1 (FN1) expression, metastatic parameters and CD8
conclusionsFAP-mediated alterations of ECM integrity, TC cells and CAFs underscore its potential as a powerful marker for tumor immunogenicity, immune infiltration and metastasis rendering it a promising therapeutic target for the treatment of aggressive ATC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.